drugset / Trial / NCT00369291
CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Giving CpG 7909 after an autologous stem cell transplant may make a stronger immune response and prevent or delay the recurrence of cancer. PURPOSE: This phase I trial is studying the side effects and best dose of CpG 7909 in treating patients who have undergone autologous stem cell transplant.
Timeline
- Start
- 2003-09
- Primary completion
- 2010-05
- Completion
- 2010-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | tetanus toxoid | Vaccine | 0.5 ml | Intramuscular |